Virtual Posters

Big Data

PO-001  ARNTL2 is a hypoxia-responsive master regulator of PDAC malignancy. Alvaro Curiel-Garcia1, Carlo H. Maurer2, Pasquale Laise3, Irina Sagalovskiy4, John A. Chabot4, Gulam A. Manji4, Alina Iuga5, Kristen Johnson6, Andrea Califano4, Kenneth P. Olive4.
1Columbia University, New York, NY, 2Technische Universität München, Munich, Germany, 3Darwin Therapeutics, New York, NY, 4Columbia University, New York, NY, 5University of North Carolina, Chapel Hill, NC, 6University of New Hampshire, Manchester, NH.

PO-002  Initial retrospective analysis of mechanisms of FOLFIRINOX resistance using clinical and molecular data from the Know Your Tumor (KYT) pancreatic ductal adenocarcinoma (PDAC) cohort. James M. Davison1, Greg Mayhew1, Kirk Beebe1, Joel R. Eisner1, Dennis Ladnier2, Eric A. Collisson3, Lynn M. Matrisian2.
1GeneCentric Therapeutics, Inc, Durham, NC, 2Pancreatic Cancer Action Network, Manhattan Beach, CA, 3Division of Hematology and Oncology, Department of Medicine and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA.

PO-003  Predictors for 30-day readmission in patients with pancreatic cancer who had DNR code status. Jasmeet Kaur1, Tanveer Mir2, Paramveer Singh3, Judie Goodman1.
1Saint Joseph Mercy Oakland Hospital, PONTIAC, MI, 2Wayne State University, Detroit, MI, 3Karmanos Cancer Center, Detroit, MI.

PO-004  Basal-like, Classical A, and Classical B subtypes of pancreatic cancer show distinct immuno-suppressive molecular profiles. Emily L. LaPlante1, Dongliang Liu1, Aleksandar Milosavljevic1, Qizhi Yao1.
1Baylor College of Medicine, Houston, TX.

PO-005  Proteome profiling of Pancreatic Ductal Adenocarcinoma (PDAC) primary tumors in Caucasian, African Americans and Latinx patients. Henry C. H. Law1, Andrea N. Riner2, Jose G. Trevino3, Nicholas T. Woods1.
1University of Nebraska Medical Center, Omaha, NE, 2University of Florida, Gainesville, FL, 3Virginia Commonwealth University, Richmond, VA.

Diagnostics, Early Detection, and Imaging

PO-006  CircRTN4 promotes pancreatic cancer progression through a novel circRNA-miRNA-lncRNA pathway and stabilizing epithelial-mesenchymal transition protein. Chi Hin Wong1, Ut Kei Lou3, Frederic Khe-Cheong Fung1, Joanna H. M. Tong2, Ka-Fai To2, Stephen Lam Chan3, Yangchao Chen4.
1School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China-Hong Kong, 2Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China-Hong Kong, 3Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China-Hong Kong, 4School of Biomedical Sciences, Faculty of Medicine, and Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong, China-Hong Kong.
PO-007  Plasma-based detection of pancreatic cancer: A multiomics approach. Teng-Kuei Hsu1, Tzu-Yu Liu1, Billie Gould1, Christine Decapite2, Amer Zureikat2, Alessandro Paniccia3, Eric Ariazi1, Marvin Bertin1, Richard Bourgon1, Kaitlyn Coil1, Hayley Donnella1, Adam Drake1, Julie M. Granka1, Preet Kaur1, Maggie C. Louie1, Shivani Mahajan1, Amit Pasupathy1, Ofer Shapira1, Peter Ulz1, Chun Yang1, C. Jimmy Lin1, Randall Brand2. 1Freenome Holdings Inc., South San Francisco, CA, 2Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, 3Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.

PO-008  Diagnostic accuracy of blood-based multi-omic biomarkers for pancreatic adenocarcinoma: A systematic review and meta-analysis. Laura E. Kane1, Gregory S. Mellotte2, Eimear Mylod1, Rebecca O'Brien1, Fiona O'Connell1, Khanh Nguyen3, Croí E. Buckley1, Jennifer Arlow3, David Mockler1, Aidan D. Meade3, Barbara M. Ryan2, Stephen G. Maher1. 1Trinity College Dublin, Dublin, Ireland, 2Tallaght University Hospital, Dublin, Ireland, 3Technological University Dublin, Dublin, Ireland.

PO-009  Multi-omic profiling of patient pancreatic cyst fluid for the identification of a novel biomarker panel of patient cancer risk. Laura E. Kane1, Gregory S. Mellotte2, Simone Marcone1, Barbara M. Ryan2, Stephen G. Maher1. 1Trinity College Dublin, Dublin, Ireland, 2Tallaght University Hospital, Dublin, Ireland.

PO-010  Detection of early tissue changes on historical CT scans in the regions of the pancreas gland that subsequently develop adenocarcinoma using quantitative textural analysis and fat fraction analysis. Ronald L. Korn1, Daniel D. Von Hoff2, Andre Burkett1, Dominic Zygdal1, Taylor Brodie3, Kathleen Panak1, Sweta Rajan1, Derek Cridebring2, Michael J. Demeure3. 1Imaging Endpoints, Scottsdale, AZ, 2Translational Genomics Research Institute, Phoenix, AZ, 3Hoag Hospital, Newport Beach, CA.

PO-011  The spectrum of pathogenic germline variants in pancreatic cancer patients with multiple primary tumors. Valentyna Kryklyva1, Lodewijk A.A. Brosens2, Marjolijn J.L. Ligtenberg1, Iris D. Nagtegaal1. 1Radboud university medical center, Nijmegen, Netherlands, 2University Medical Center Utrecht, Utrecht, Netherlands.

PO-012  The concept of artificial intelligence against pancreatic cancer. Subash Kumar1. 1DMI Lochbridge, Elkridge, MD.

PO-013  Comparison of novel healthcare delivery models on the uptake of genetic education and testing in families with a history of pancreatic cancer: The GENetic Education, Risk Assessment and TESting (GENERATE) Study. Nicolette J. Rodriguez1, Constance S. Furniss2, Matthew B. Yurgelun3, Chinedu Ukaegbu4, Pamela E. Constantinou5, Alison N. Schwartz4, Jill Stopfer4, Meghan Underhill-Blazey6, Barbara Kenner7, Scott Nelson8, Sydney Okumura9, Sherman Law9, Alicia Y. Zhou9, Tara B. Coffin10, Hajime Uno9, Allysyn Ocean11, Florencia McAllister5, Andrew M. Lowy12, Scott M. Lippman12, Alison P. Klein13, Lisa Madlensky12, Gloria M. Petersen14, Judy E. Garber1, Michael G. Goggins13, Anirban Maitra5, Sapna Syngal3. 1Dana-Farber Cancer Institute / Brigham and Women's Hospital / Harvard
PO-014  VISTA: VIsual Semantic Tissue Analysis for pancreatic disease quantification in murine cohorts. Luke Ternes¹, Ge Huang¹, Christian Lanciaut¹, Guillaume Thibault¹, Rachelle Riggers², Joe Gray², John Muschler¹, Young Hwan Chang¹. ¹Oregon Health and Science University, Portland, OR, ²Oregon Health and Science University, Portland, OR.

Early Phase Clinical Trials

PO-015  A phase Ib/II trial of high dose ascorbic acid (AA) + paclitaxel protein bound (PP) + cisplatin (C) + gemcitabine (G) in patients (pts) with previously untreated metastatic pancreatic cancer (MPC). Gayle S. Jameson¹, Erkut H. Borazanci¹, Daniel D. Von Hoff², Joshua D. Rabinowitz³, Michael S. Gordon¹, Sarah D. LeGrand¹, Courtney Snyder¹, Karen Ansaldo¹, Denise J. Roe⁴, Haiyong Han². ¹HonorHealth, Scottsdale, AZ, ²Translational Genomics Research Institute (TGen), Phoenix, AZ, ³Princeton University, Princeton, NJ, ⁴University of Arizona Cancer Center, Tucson, AZ.

Immunotherapy

PO-016  Directed evolution generates novel oncolytic H-1 parvoviruses with improved therapeutic efficacy in virus-resistant pancreatic cancer cells. Pierre Garcin¹, Monireh Kazemimanesh¹, Hubert Lulka¹, Nelson Dusetti², Guillaume Labrousse³, Emilie Benuzzi¹, Louis Buscail³, Pierre Cordelier¹. ¹Cancer Research Center of Toulouse, INSERM, Toulouse, France, ²Cancer Research Center of Marseilles, INSERM, Marseilles, France, ³Cancer Research Center of Toulouse, INSERM and Toulouse University Hospital, Toulouse, France.

PO-017  Application of oncolytic adenovirus to desmoplastic pancreatic cancer. Elora Hossain¹, Fumihiro Higashino¹. ¹Hokkaido University, Sapporo, Japan.

PO-018  Inflaming advanced solid tumors including pancreatic cancer using LOAd703, a TMZ-CD40L/4-1BBL-armed oncolytic virus. Jessica Wenthé¹, Emma Eriksson², Linda Sandin³, Tanja Lövgren², Justyna Leja Jarblad³, Hanna Dahlstrand³, Ulla Olsson-Strömberg⁴, Aglaia Schiza⁴, Anders Sundin⁴, Sandra Irenaeus⁴, Eric Rowinsky⁵, Gustav Ullenbag⁴, Angelica Loskog⁶. ¹Uppsala University, Uppsala, Sweden, ²Uppsala university, Uppsala, Sweden, ³Lokon Pharma AB, Uppsala, Sweden, ⁴Uppsala University Hospital, Uppsala, Sweden, ⁵Lokon Pharma AB, New York, NY, ⁶Uppsala University & Lokon Pharma AB, Uppsala, Sweden.
PO-019 Reprogramming of naïve B cells in pancreatic cancer subverts humoral immunity. Bhalchandra Mirlekar1, Yuliya Pylayeva-Gupta1, 1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.

PO-020 Heating up immune cold pancreatic adenocarcinoma with bioengineered immunotherapy remodels tumor microenvironment and prevents metastasis in vivo. Chanthirika Ragulan1, Patrick Varun Lawrence1, Hari PS1, Krisha Desai1, Jun Ishihara2, Anguraj Sadanandam1. 1The Institute of Cancer Research, Sutton, United Kingdom, 2Imperial College London, London, United Kingdom.

Metabolism

PO-021 Targeting the mitochondrial pyruvate complex to alter metabolic programming in pancreatic cancer. Hassan A. Ali1, Andrew Metcalfe2, James T. Topham2, Cassia S. Warren2, Joanna M. Karasinska2, David F. Schaeffer2, Daniel J. Renouf2. 1University of British Columbia, Vancouver, BC, Canada, 2Pancreas Centre BC, Vancouver, BC, Canada.

PO-022 Exploiting a redox bottleneck to combat drug tolerance in pancreatic cancer. Holly Brunton1, Ludimila Cavalcante2, David Sumptom1, Francis Giles2, Owen Sansom1. 1CRUK Beatson Institute, Glasgow, United Kingdom, 2Actuate Therapeutics, Fort Worth, TX.

PO-023 Impaired adipose anabolism drives fat wasting in pancreatic cancer cachexia. Katherine Pelz1, Grace McCarthy1, Heike Mendez1, Samantha Z. Brown1, Jonathan R. Brody1, Aaron J. Grossberg1. 1Oregon Health & Science University, Portland, OR.

PO-024 Targeting cellular metabolism with CPI-613 sensitizes pancreatic cancer cells to radiotherapy. William A. Hall1, Husain Y. Khan2, Mandana Kamgar1, Susan Tsai1, Kathleen Christians1, Douglas B. Evans1, Philip Philip2, Callisia Clarke1, Ben George1, Beth Erickson1, Asfar S. Azmi2. 1Medical College of Wisconsin, Milwaukee, WI, 2Karmanos Cancer Institute, Wayne State University, Detroit, MI.

PO-025 Investigating lipid homeostasis in pancreatic ductal adenocarcinoma under tumor-like stress. Yanqing (Christine) Jiang1, Xu Han, Michelle Burrows, Celeste Simon, Xianxian Huang2, Juanfei Peng1, Yanyan Zhuang1, Yuanhua Li3, Junchi Qu1, Shineng Zhang1, Xu Han, Michelle Burrows, Carson Poltorack, Celeste Simon, Brian Keith. University of Pennsylvania, Philadelphia, PA.

PO-026 CircMYOF acts as a miR-4739 sponge to promote progression and facilitate glycolysis via VEGFA/PI3K/AKT pathway in pancreatic ductal adenocarcinoma. Dandan Zheng1, Xianxian Huang2, Juanfei Peng1, Yanyan Zhuang1, Yuanhua Li3, Junchi Qu1, Shineng Zhang1, Fengting Huang1. 1Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, 2the Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China, 3Tungwah Hospital of Sun Yat-sen University, Dongguan, China.

PO-028  Pancreatic ductal adenocarcinoma is dependent on an unconventional pathway for polyamine synthesis. Min-Sik Lee, Insia Naqvi, Courtney Dennis, Lucas Dailey, Alireza Lorzadeh, Tamara Zaytouni, Ashley Adler, Daniel S. Hitchcock, Lin Lin, Unmesh JadHAV, Clary B. Clish, and Nada Y. Kalaany. 1Division of Endocrinology, Boston Children’s Hospital, Boston, MA, 2Department of Pediatrics, Harvard Medical School, Boston, 3Broad Institute of MIT and Harvard, Cambridge, MA, 4Metabolomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA, 5Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 6Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA.

PO-029  Pancreatic cancer-associated cachexia as a 3-stage systemic disease with changes in body composition, tissue-specific wasting across time and alterations in glucose metabolism. Blanca Majem, Insia Naqvi, Courtney Dennis, Lucas Dailey, Clary B. Clish, Nada Kalaany. 1Boston Children’s Hospital, Harvard Medical School, Boston, MA, 2Metabolomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA.

PO-031  Lysosome inhibition overcomes resistance to CDK4/6 inhibition in PDA. Dilru Silva, Conan Kinsey, Martin McMahon. Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.

PO-032  Ketogenic diet and chemotherapy combine to disrupt pancreatic cancer metabolism and growth. Lifeng Yang, Joshua Rabinowitz. Princeton University, Princeton, NJ.

Microbiome


Other

PO-034  CPSF3 inhibition halts pancreatic cancer cell proliferation by limiting core histone supplies. Abdulrahman A. Alahmari, Carla Schwarz, Emily Paterson, Swati Venkat, Arwen Tisdale, Michael E. Feigin. 1Roswell Park Comprehensive Cancer Center, Amherst, NY, 2Roswell Park Comprehensive Cancer Center, Buffalo, NY.

PO-036  LP184, a novel alkylating agent, is highly effective in pancreatic cancers with DNA damage repair defects. Diana Restifo, Aditya Kulkarni, Caleb Schimke, Joseph McDermott, Umesh Kathad, Kishor Bhatia, Panna Sharma, Igor Astsaturov. 1Fox Chase Cancer Center, Philadelphia, PA, 2Lantern Pharma, Dallas, TX.

PO-037  Development of an RGD CRISPR-modified Clostridium novyi NT Spores as
an Intravenous Oncotherapy. Kaitlin M. Dailey1, Krysten Vance2, Kyle McAndrews3, Reed I. Jacobson4, Jandro Delgado4, Paige R. Johnson5, Taylor M. Woolery5, Megan Orr6, Jiha Kim7, Sanku Mallik5, Kenneth W. Bayles8, Michael A. Hollingsworth2, Amanda E. Brooks9. 1Eppley Institute for Cancer Research, University of Nebraska Medical Center, and Cell and Molecular Biology Program, Pharmaceutical Sciences Department, North Dakota State University, Omaha, NE, 2Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE, 3Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, Omaha, NE, 4Department of Biological Sciences, North Dakota State University, Fargo, ND, 5Cell and Molecular Biology Program, Pharmaceutical Sciences Department, North Dakota State University, Fargo, ND, 6Department of Statistics, North Dakota State University, Fargo, ND, 7Cell and Molecular Biology Program, Pharmaceutical Sciences Department and Department of Biological Sciences, North Dakota State University, Fargo, ND, 8Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, 9Cell and Molecular Biology Program, Pharmaceutical Sciences Department, North Dakota State University, Fargo, ND and Department of Research and Scholarly Activity, Rocky Vista University, Ivins, UT, Fargo, ND.

PO-038 LAMC2: new player in stemness and tumor progression in pancreatic cancer. Donatella Delle Cave1, Tea Teresa Iavazzo1, Maria Mangini2, Gennaro Andolfi1, Teresa Pirozzi1, Annalisa Di Domenico1, Annachiara De Luca2, Enza Lonardo1. 1Institute of Genetics and Biophysics ‘Adriano Buzzati-Traverso’ (IGB), CNR, Naples, Italy, 2Institute of Biochemistry and Cellular Biology, National Research Council of Italy, Naples, Italy.

PO-039 Antiproliferative activity of inhibitors of RAD51, singly and in combination with chemotherapy drugs, against pancreatic cancer cell lines. Peter Ferguson1, Mark D. Vincent1, Yousef Najajreh2, Brian Shilton3, Stephen Ritter3, Rima Al-award4, Richard Marcellus4, Mohammed Mohammed4, Methvin Isaac5, James Koropatnick4. 1London Health Sciences Centre, London, ON, Canada, 2Al Quds University, Jerusalem, Palestinian Territory, 3Western University, London, ON, Canada, 4Ontario Institute for Cancer Research, Toronto, ON, Canada.

PO-040 Nischarin is expressed in pancreatic ductal adenocarcinoma and is a potential target for drug repurposing. Jelena Grahovac1, Marijana Pavlovic1, Marija Ostojic1, Kristina Zivic1, Daniel Galun2, Tatjana Srdic-Rajic1. 1Institute for Oncology and Radiology of Serbia, Belgrade, Serbia, 2School of Medicine, University of Belgrade; First Surgical Clinic, Clinical Center of Serbia, Belgrade, Serbia.

PO-041 Systemic screening of gene delivery methods in pancreatic ductal adenocarcinoma cells. Dmytro Grygoryev1, Taelor Ekstrom1, Jason M. Link2, Rosalie C. Sears2, Jungsun Kim1. 1Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Portland, OR, 2Oregon Health & Science University, Portland, OR.

PO-042 ANGPTL4 accelerates KRASG12D-induced acinar to ductal metaplasia and pancreatic carcinogenesis. Kyung Hee Jung1, Young-Chan Youn1, Soon-Sun Hong1. 1College of Medicine, Inha University, Incheon, Republic of Korea.
PO-043  Cytidine deaminase protects pancreatic cancer cells from replicative stress and drive response to DNA-targeting drugs. Audrey Lumeau1, Nicolas Bery1, Cyril Ribeyre2, Samad Elkaoutari3, Guillaume Labrousse1, Miguel Madrid-Mencia1, Vera Pancaldi1, Marie-Jeanne Pillaire4, Valérie Bergoglio5, Nelson Dusseti3, Jean-Sébastien Hoffmann6, Louis Buscail7, Malik Lutzmann2, Pierre Cordelier1. 1Cancer Research Center of Toulouse, Toulouse, France, 2IGH Montpellier, Montpellier, France, 3Cancer Research Center of Marseille, Marseille, France, 4IPBS Toulouse, Toulouse, France, 5CBI Toulouse, Toulouse, France, 6IUCT Oncopole Toulouse, Toulouse, France, 7CHU Rangueil Toulouse, Toulouse, France.


PO-045  Targeting HNF1A-dependent cell proliferation and stemness in PDAC using BET inhibitors. Bharani Muppavarapu, Ethan Abel, Melanie Mayberry. Roswell Park Comprehensive Cancer Center, Buffalo, NY.

PO-046  The effect of neoadjuvant therapy on immune profiling of pancreatic ductal adenocarcinoma: a prospective study of the PREOPANC-1 randomized controlled trial. Diba Latifi, Willem de Koning, Sai ping Lau, Frederiek Grevers, Coen van Dam, Casper H. J. van Eijck, Dana A. M. Mustafa. Erasmus University Medical Center, Rotterdam, Netherlands.

PO-047  Optimizing the efficacy of 5-FU as a chemotherapeutic agent in advanced pancreatic ductal adenocarcinoma (PDAC) using MIA PaCa-2 and PANC-1 cells. Nkafu Bechem Nd emazie1, Andriana Inkoom1, Xue Y. Zhu1, Edward Agyare1. 1Florida A&M University, Tallahassee, FL.

PO-048  A novel chromatin remodeling domain of keratin 17 regulates transcription and promotes tumor aggression in pancreatic cancer. Chun-Hao Pan1, Robert Tseng1, Simon J. Hogg2, Gabriella Baraks1, Cindy V. Leiton1, Lucia Roa-Peña1, Natalia Marchenko1, Kenneth R. Shroyer1, Luisa F. Escobar-Hoyos3, 1Stony Brook University, Stony Brook, NY, 2Memorial Sloan Kettering Cancer Center, New York, NY, 3Yale University, New Haven, CT.

PO-049  Inhibiting MNK kinases promotes macrophage immunosuppressive phenotype to limit anti-tumor immunity. Thao ND Pham1, Christina Spaulding1, Mario A. Shields1, Mahmoud G. Khalafalla1, Daniel R. Prince2, David J. Bentrem1, Hidayatullah G. Munshi1. 1Feinberg School of Medicine, Northwestern University, Chicago, IL, 2Medical Scientist Training Program, College of Medicine, University of Illinois at Chicago, Chicago, IL.

PO-050  Precision Promise (PrP): An adaptive, multi-arm registration trial in metastatic pancreatic ductal adenocarcinoma (PDAC). Vincent J. Picozzi1, Anne-Marie Duliege2, Anirban Maitra3, Manuel Hidalgo4, Andrew Eugene Hendifar5, Gregory L. Beatty6, Sudheer Doss Doss2, Regina Deck2, Lynn M. Matrisian2, Julie Fleshman2, Diane M. Simeone7. 1Virginia Mason Hospital and Medical Center, Seattle, WA, 2Pancreatic Cancer Action Network, Manhattan Beach, CA, 3University of Texas MD Anderson Cancer Center, Houston, TX, 4Weill
PO-051  **PANOVA-3: A phase III study of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally advanced pancreatic adenocarcinoma.** Vincent J. Picozzi¹, Teresa Macarulla², Philip A. Philip³, Carlos R. Becerra⁴, Tomislav Dragovich⁵. ¹Virginia Mason Hospital and Medical Center, Seattle, WA, ²Vall d'Hebrón University Hospital and Vall d'Hebrón Institute of Oncology, Barcelona, Spain, ³Karmanos Cancer Institute, Detroit, MI, ⁴Baylor University Medical Center, Dallas, TX, ⁵Banner MD Anderson Cancer Center, Gilbert, AZ.

PO-052  **A pilot study of miRNA expression profile in surgically resected pancreatic ductal adenocarcinoma: Initial report from a bi-institutional cohort.** Luca Pompella¹*, Michela Falco²*, Carlo Caputo², Anna Grimaldi³, Giuseppe Tirino¹, Severo Campione³, Francesca Sparano¹, Maria Lucia Iacovino¹, Chiara Carmen Miceli¹, Carlo Molino⁴, Marco Montella⁵, Renato Franco⁵, Gennaro Galizia⁶, Giovanni Conzo⁷, Vincenzo Napolitano⁷, Annamaria Auricchio⁶, Francesca Cardella⁶, Fortunato Ciardiello¹, Michele Caraglia², Angela Lombardi², Gabriella Misso² and Ferdinando De Vita¹*. ¹Department of Precision Medicine, Division of Medical Oncology, University of Campania "L. Vanvitelli", Aversa, Italy, ²Department of Precision Medicine, Division of Molecular Pathology, University of Campania "Luigi Vanvitelli", Naples, Italy, ³Department of Precision Medicine, Division of Medical Oncology, University of Campania "L. Vanvitelli", Naples, Italy, ⁴Division of Surgical Pathology, AORN "Antonio Cardarelli", Naples, Italy, ⁵Division of General Surgery 1, AORN "Antonio Cardarelli", Naples, Italy, ⁶Division of Surgical Pathology, University of Campania "Luigi Vanvitelli", Naples, Italy, ⁷Department of Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy. * These authors contributed equally to this work.

PO-054  **A phase II trial of the super-enhancer inhibitor Minnelide in advanced refractory adenosquamous carcinoma of the pancreas (ASCP).** Nebojsa Skorupan¹, Mehwish I. Ahmad¹, Seth M. Steinberg¹, Jane B. Trepel¹, Derek Cridebring², Haiyong Han², Daniel D. Von Hoff², Christine Alewine¹. ¹CCR, Bethesda, MD, ²Translational Genomics Research Institute, Phoenix, AZ.

PO-055  **Phase II clinical trial of subtype directed neoadjuvant therapy in patients with localized pancreatic cancer.** Susan Tsai¹, Erkut Borazanci², Margaret Gulley³, Naim Rashid³, Jason Merker³, Abdul H Khan¹, Phillip Chisholm¹, Bryan Hunt¹, Tamara Giorgadze¹, William Hall¹, Mandana Kamgar¹, Douglas B Evans¹, Jen Jen Yeh³. ¹Medical College of Wisconsin, Milwaukee, WI, ²Honor Health Medical Group, Scottsdale, AZ, ³University of North Carolina,
Chapel Hill, NC.

PO-056 Insulin receptor signaling in pancreatic acinar cells contributes to pancreatic cancer development. Anni M.Y. Zhang, Jenny C.C. Yang, Twan J.J. de Winter, David F. Schaeffer, Janel L. Kopp, James D. Johnson. The University of British Columbia, Vancouver, BC, Canada.

PO-057 Targeting ErbB2 degradation via the ubiquitin–proteasome pathway to inhibit the metastasis of pancreatic cancer. Bo Zhang, Fei Teng, Nengming Lin. Hangzhou First People's Hospital, Hangzhou, China.

Preclinical Models

PO-058 Anti-cancer activity of NTAX-44 (bioprocessed arsenic trioxide) on pancreatic cancer cell line. Yogesh Bendale¹, Padma Shastri², Radha Poojari³, Nandine Khot², Surendra Nagare², Avinash Kadam². ¹Rasayu Cancer Clinic, Pune, India, ²Rasayani Biologics Pvt. Ltd, Pune, India, ³Innovation Centre, Tata Chemicals Ltd., Pune, India.

PO-059 Epithelial/mesenchymal identity dictates pancreatic cancer cell metastasis. Julienne L. Carstens¹, Sujuan Yang¹, Pedro Correa de Sampaio¹, Xiaofeng Zheng¹, Souptik Barua⁰, Kathleen M. McAndrews¹, Arvind Rao³, Jared K. Burks¹, Andrew D. Rhim¹, Raghu Kalluri¹. ¹MD Anderson Cancer Center, Houston, TX, ²Rice University, Houston, TX, ³University of Michigan, Ann Arbor, MI.

PO-060 N-terminal RHAMM cooperates with dysfunctional p53 to accelerate the progression of pancreatic cancer. Anthony Lin¹, Jennifer Feng¹, Xiang Chen¹, Dunrui Wang², Megan Wong¹, George Zhang¹, Joseph Na¹, Tiantian Zhang¹, Zhengming Chen¹, Yao-Tseng Chen¹, Yi-Chieh Nancy Du¹. ¹Weill Cornell Medicine, New York, NY, ²National Institutes of Health, Bethesda, MD.

PO-061 Myc drives phenotypic heterogeneity, metastasis, and therapy resistance in pancreatic ductal adenocarcinoma. Isabel A. English¹, Patrick J. Worth¹, Amy T. Farrell¹, Brittany L. Allen-Petersen², Vidhi Shah¹, Courtney Betts¹, Xiaoyan Wang¹, Colin J Daniel¹, Mary C. Thoma¹, Lisa M. Coussens¹, Ellen M. Langer¹, Rosalie C. Sears¹. ¹Oregon Health & Science University, Portland, OR, ²Purdue University, West Lafayette, IN.

PO-062 EUS-guided biopsy of pancreatic mass lesions for the development of patient-derived organoids in Puerto Rico. Andrea S. Flores Pérez¹, Janet Mendez Vega¹, Ana M. Reyes Ramos¹, Carlos Micames³, Madeline Torres-Lugo¹, Maribella Domenech¹. ¹University of Puerto Rico - Mayagüez, Mayagüez, Puerto Rico, ²Hospital Bella Vista, Mayagüez, Puerto Rico.

PO-063 Functional interrogation of immune escape in neoantigen-expressing pancreatic cancer identifies a critical role for the CD155/TIGIT axis. William Freed-Pastor¹, Laurens Lambert¹, Zackery Ely¹, Nimisha Pattada¹, Arjun Bhutkar¹, Alex Jaeger¹, George Eng¹, Kim Mercer¹, William Hwang¹, Tyler Jacks¹. ¹MIT, Cambridge, MA.
PO-064  ONC212 stimulates cytotoxic T-cell killing, increases tumor-immune cell interactions, and promotes tumor regression in combination with TLY012 in a PDAC murine model. Kelsey E. Huntington¹, Anna Louie¹, Young Lee¹, Jared Mompoint¹, Isacco Ferrarini², Aakash Jhaveri³, Varun V. Prabhu⁴, Allen Melemed⁴, Seulki Lee⁵, Wafik S El-Deiry¹. ¹Brown University, Providence, RI, ²University of Verona, Verona, Italy, ³Sidney Kimmel Medical College, Philadelphia, PA, ⁴Chimerix, Durham, NC, ⁵D&D Pharmatech, Gaithersburg, MD.

PO-065  SIWA318H, an advanced glycation end product (AGE) targeting antibody, is efficacious in a humanized mouse xenograft model for pancreatic cancer. Ashley Jensen¹, Gabriela R. Rossi², Ruben Muñoz¹, Kimberly Brothers¹, Lewis Gruber², Misty Gruber², Haiyong Han¹. ¹Translational Genomics Research Institute, Phoenix, AZ, ²SIWA Therapeutics, Inc., Chicago, IL.

PO-066  High uptake, retention, and in vivo activity of L-Annamycin in pancreatic cancer models. Ya'an Kang, Rafal Zielinski, Roberto Cardenas Zuniga, Radjendirane Venugopal, Maria Poimenidou, Magdalena Remiszewska, Shaohua Peng, Edd Felix, Krzysztof Grela, Stanislaw Skora, Van N. Nguyen, Izabela Fokt, Waldemar Priebé. UT MD Anderson Cancer Center, Houston, TX.

PO-067  A multi-omics study in patient-derived organoids reveals MNX1-HNF1B axis to be indispensable for intraductal mucinous papillary neoplasm lineages. Hiroyuki Kato¹, Keisuke Tateishi¹, Keisuke Yamamoto¹, Dousuke Iwadate¹, Hiroaki Fujiwara², Takuma Nakatsuka¹, Koji Miyabayashi¹, Yotaro Kudo¹, Ijichi Hideaki¹, Kazuhiko Koike², Mitsuhiko Fujishiro¹. ¹Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Division of Gastroenterology, The Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan, ³Department of Gastroenterology, Kanto Central Hospital, Tokyo, Japan.

PO-068  Cholesterol auxotrophy promotes the expansion of centroacinar cells giving rise to the basal subtype of pancreatic adenocarcinoma. Michael Kotliar¹, Aizhan Surumbayeva², Linara Gabitova², Suraj Peri³, Diana Restifo², Kathy Q. Cai⁴, Artem Barski⁵, Igor Astsaturov². ¹Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²The Marvin & Concetta Greenberg Pancreatic Cancer Institute, Fox Chase Cancer Center, Philadelphia, PA, ³Biostatistics and Bioinformatics Facility, Fox Chase Cancer Center, Philadelphia, PA, ⁴Histopathology Facility, Fox Chase Cancer Center, Philadelphia, PA, ⁵Cincinnati Children’s Hospital Medical Center and Department of Pediatrics, University of Cincinnati, Cincinnati, OH.

PO-069  Modeling the tumor microenvironment using tissue engineering technologies. Rodrigo Curvello¹, Verena Kast², Daniela Loessner¹. ¹Monash University, Clayton, Australia, ²Max Bergmann Center of Biomaterials Dresden, Dresden, Germany.

PO-070  Longitudinal precision oncology platform to identify chemotherapy-induced vulnerabilities in pancreatic cancer. Katja Peschke¹, Hannah Jakubowski¹, Arlett Schäfer¹, Carlo Maurer¹, Sebastian Lange¹, Felix Orben¹, Raquel Bernad¹, Felix Harder¹, Matthias Eiber¹.

AACR Virtual Special Conference: PANCREATIC CANCER | September 29-30, 2021
Rupert Öllinger¹, Melissa Schlitter¹, Wilko Weichert¹, Veit Phillip¹, Christoph Schlag¹, Roland Schmid¹, Rickmer Braren¹, Bo Kong², Ekin Demir¹, Helmut Friess¹, Roland Rad¹, Dieter Saur¹, Günter Schneider¹, Maximilian Reichert¹. ¹Technical University of Munich, Klinikum rechts der Isar, Munich, Germany, ²University of Ulm, Ulm, Germany.

PO-072 Inhibiting vasoactive intestinal peptide receptor signaling elicits T cell dependent anti-tumor response of pancreatic ductal adenocarcinoma to immune checkpoint therapy. Sruthi Ravindranathan¹, Passang Tenzin¹, Jian Ming Li¹, Rohan Dhamsania¹, Michael Ware¹, Mohammad Zaidi¹, Shuhua Wang¹, Jingru Zhu¹, Maria Cardenas¹, Yuan Liu¹, Gaurav Joshi¹, Sanjeev Gumber¹, Brian Robinson¹, Anish Sen-Majumdar², Shanmuganathan Chandrakasan¹, Haydn Kissick¹, Alan Frey², Susan Thomas³, Bassel El-Rayes¹, Gregory Lesinski¹, Edmund K. Waller¹. ¹Emory University, Atlanta, GA, ²Cambium Oncology, Atlanta, ³Georgia Institute of Technology, Atlanta.

PO-073 Inactivation of Notch4 attenuated pancreatic tumorigenesis in mice. Kiyoshi Saeki¹, Wanglong Qiu¹, Richard Friedman¹, Carrie Shawber¹, Jan Kitajewski², Jianhua Hu¹, Gloria H. Su¹. ¹Columbia University Irving Medical Center, New York, NY, ²University of Illinois Chicago, Chicago, IL.

PO-074 Identification of C-MET receptor as a therapeutic target in patient-specific tumoroid models of metastatic pancreatic adenocarcinoma allows identification of a new mode of action for its inhibitors. Liam Deems, Maria Ivanova, Cheryl Murphy, Amit Shahar, David Deems, Dmitry Shvartsman. Cellaria Inc., Wakefield, MA.

PO-075 The elucidation of the role of Prrx1 for acinar to ductal metaplasia in response to acute injury of pancreas in the novel mouse models. Kensuke Suzuki¹, Alina Li¹, Jason R. Pitarresi¹, Anna M. Chiarella¹, Gizem Efe¹, Kensuke Sugiura¹, Rohit Chandwani², Anil K. Rustgi¹. ¹Herbert Irving Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, ²Department of Surgery, Weill-Cornell Medical School, New York, NY.


PO-077 Establishment of a novel living biobank of patient-derived pancreatic cancer organoids with genomic and drug response characterization. Irene Y. Xie¹, Laura Tamblyn², Karen Ng², Eugenia Flores-Figueroa², Julie M. Wilson³, Gun Ho Jang³, Amy X. Zhang³, Stephanie Ramotar², Anna Dodd², Nikolina Radulovich², Jennifer J. Knox², Grainne M. O’Kane², Steven Gallinger², Faiyaz Notta². ¹University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Ontario Institute of Cancer Research, Toronto, ON, Canada.
PO-079  Proteomic profiling reveals subtype specific kinase expression in pancreatic cancer. Yi Xu, Michael East, Ashley Morrison, Gabriela Herrera, Laura Peng, Gary Johnson, Jen Jen Yeh. UNC Chapel Hill, Chapel Hill, NC.


Signaling

PO-081  Studying MYC’s contribution to replication stress at the nuclear pore. Gabriel M. Cohn, Colin J. Daniel, Daniel F. Liefwalker, Rosalie C. Sears. Oregon Health & Science University, Portland, OR.

PO-082  Delineating the molecular basis of early dissemination of pancreatic cancer. Taelor Ekstrom¹, Dmytro Grygoryev¹, Terry Morgan², Kenneth S Zaret³, Jungsun Kim⁴. ¹Cancer Early Detection Advanced Research Center, Oregon Health & Science University, Portland, OR, ²Cancer Early Detection Advanced Research Center, Department of Pathology, Knight Cancer Institute (Cancer Biology Research Program), Oregon Health & Science University School of Medicine, Portland, OR, ³Institute for Regenerative Medicine, Department of Cell and Developmental Biology, Abramson Cancer Center (Tumor Biology Program), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁴Cancer Early Detection Advanced Research Center, Department of Molecular and Medical Genetics, Knight Cancer Institute (Cancer Biology Research Program), Oregon Health & Science University School of Medicine, Portland, OR.

PO-084  The role of p53 in the development of pancreatic ductal adenocarcinoma. Kathryn J. Hanson, Brittany M. Flowers, Nicholas Hughes, Hannes Vogel, Le Cong, Laura D. Attardi. Stanford University, Stanford, CA.


PO-087  SCAP-SREBP signaling is essential for acinar cell differentiation and maintenance, and pancreatic morphogenesis, influencing resident pools of cancer-forming progenitor cells. Anna C. Lilly, Aizhan Surumbayeva, Erica A Golemis, Igor Astsaturov. Fox Chase Cancer Center, Philadelphia, PA.

PO-088  Classification based on efficiency of mRNA translation reveals a metabolically-dependent subtype of pancreatic cancer. Sauyeun Shin¹, Remy Nicolle², Mehdi Liauzun¹,
Identification of a LAMC2-regulated network featuring targetable effectors for dual therapies in pancreatic cancer. Shruthi Narayanan1, Oihane Erice2, Iker Feliú2, Caterina Vicentini3, Rodrigo Entrialgo-Cadierno2, Karmele Valencia2, Elisabet Guruceaga4, Purvesh Khatri5, Vicenzo Corbo5, Silvestre Vicent Cambra6, Mariano Ponz-Sarvise1. 1Clinica Universidad de Navarra, Medical Oncology Department, Pamplona, Spain, 2University of Navarra, Center for Applied Medical Research, Program in Solid Tumors, Pamplona, Spain, 3Department of Diagnostics and Public Health, University of Verona, Verona, Italy, 4University of Navarra, Center for Applied Medical Research, Computational Biology Program, Pamplona, Spain, 5Stanford University, Stanford, CA, 6University of Navarra, Center for Applied Medical Research, Program in Solid Tumors and Department of Pathology, Anatomy and Physiology; IdiSNA, Navarra Institute for Health Research; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain, Pamplona, Spain.

TGF-β induced EMT gene expression is associated with promoter demethylation in pancreatic cancer. Manjul Rana1, Abul Elahi1, Abidemi O. Ajidahun1, Rita G. Kansal1, Anders E. Berglund2, David Shibata1, Evan S. Glazer1. 1UTHSC, Memphis, TN, 2Moffitt Cancer Center, Tampa, FL.

Histamine receptor 1 (HRH1): A potentially novel G protein-coupled receptor (GPCR) therapeutic target in pancreatic adenocarcinoma (PDAC) cells and tumors. Cristina Salmeron, Krishna Sriram, Mehrak Javadi-Paydar, Paul A. Insel. 1UCSD, La Jolla, CA.

Influence of the IL-13-receptor alpha 1 chain on the malignant phenotype of pancreatic cancer cells. Jingwei Shi, Marko Kornmann, Benno Traub. University of Ulm, Ulm, Germany.

JNK2 suppresses the growth and invasion of pancreatic cancer and is opposed by JNK1. Jingwei Shi, Xiaodong Tian, Marko Kornmann, Benno Traub. University of Ulm, Ulm, Germany.

Gu13 loss in KPC mouse model promotes well-differentiated pancreatic tumors that are susceptible to mTOR inhibition. Mario A. Shields, Christina Spaulding, Mahmoud G. Khalafalla, Thao N. D. Pham, Hidayatullah G. Munshi. Northwestern University, Chicago, IL.

Tumor Microenvironment
PO-095  A cancer cell-intrinsic GOT2-PPARD axis suppresses antitumor immunity. Jaime Abrego¹, Hannah Sanford-Crane¹, Chet Oon¹, Xu Xiao², Courtney Betts¹, Duanchen Sun³, Shanthi Nagarajan⁴, Zheng Xia³, Lisa Coussens¹, Peter Tontonoz⁵, Mara Sherman¹. ¹Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR, ²Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, ³Computational Biology Program, Oregon Health & Science University, Portland, OR, ⁴Medicinal Chemistry Core, Oregon Health & Science University, Portland, OR, ⁵Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.

PO-096  The synaptic protein Netrin G1 ligand (NGL-1) modulates tumorigenesis and immunosuppression in pancreatic cancer. Debora Barbosa Vendramini Costa¹, Ralph Francescone¹, Janusz Franco-Barraza¹, Tiffany Luong¹, Nina Steele², Benjamin Allen², Marina Pasca di Magliano³, Charline Ogier¹, Igor Astsaturov¹, Kathy Q Cai¹, Andres J Klein-Szanto¹, Huamin Wang⁴, Kerry Campbell¹, Edna Cukierman¹. ¹Fox Chase Cancer Center, Philadelphia, PA, ²Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, MI, ³Department of Surgery, University of Michigan, Ann Arbor, MI, ⁴Department of Anatomical Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

PO-097  Addition of losartan to FOLFIRINOX and chemoradiation reduces the expression of pro-invasive and immunosuppressive genes in locally-advanced pancreatic cancer. Yves Boucher¹, Jessica M. Posada², Sonu Subudhi², Ashwin S. Kumar², Ivy X. Chen², Mei R. Ng², Mari Mino-Kenudson², Nilesh Talele², Dan G. Duda², Dai Fukumura³, Janet E. Murphy³, Jeffrey W. Clark³, David P. Ryan³, Carlos Fernandez-Del Castillo³, Theodore S. Hong³, Rakesh K. Jain³. ¹Massachusetts General Hospital and Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Harvard Medical School, Boston, MA.

PO-098  Longitudinal profiling of pancreatic cancer patients identifies interleukin-8 as a mediator of myeloid-epithelial crosstalk. Eileen S. Carpenter¹, Samantha Kemp², Padma Kadiyala¹, Nina Steele¹, Ahmed Ehloossiy¹, Stephanie The¹, Valerie Gunchick¹, Rémy Nicolle³, Michelle Anderson¹, Wenting Du¹, Carlos Espinoza¹, Richard Kwon¹, Erik-Jan Wamsteker¹, Anoop Prabhu¹, Allison Schulman¹, Vaibhav Sahai¹, Timothy Frankel¹, Filip Bednar¹, Marina Pasca di Magliano¹. ¹University of Michigan, Ann Arbor, MI, ²University of Pennsylvania, Philadelphia, PA, ³Tumour Identity Card Program (CIT), French League Against Cancer, Paris, France.

PO-100  Lorazepam promotes desmoplasia and ischemic necrosis in murine pancreatic ductal adenocarcinoma. Abigail C. Cornwell, Abdulrahman A. Alahmari, Arwen A. Tisdale, Kathryn Maraszek, Swati Venkat, Michael E. Feigin. Roswell Park Comprehensive Cancer Center, Buffalo, NY.

PO-101  Characterization of longitudinally collected fine needle aspiration biopsies of pancreatic ductal adenocarcinoma upon endoscopic ultrasound guided radiofrequency ablation. Krisha Desai¹, Patrick Varun Lawrence¹, Christopher Wadsworth², Nagina Mangal²,
Fibroblast-derived interleukin-33 promotes pancreatic ductal adenocarcinoma as a result of tumor cell KRAS$^{G12D}$, Katelyn Donahue, Wenting Du, Carlos Espinoza, Eileen Carpenter, Kristee Brown, Nina Steele, Marina Pasca di Magliano. University of Michigan, Ann Arbor, MI.

Cellular origin influences immune microenvironment in a pancreatic cancer mouse model with loss of Pten and activation of Kras. Yan Dou, Wesley Hunt, Justin Chhuor, Farnaz Taghizadeh, Atefeh Samani, Karnjit Sarai, Claire Dubois, David F. Schaeffer, Maite Sander, Janel L. Kopp. University of British Columbia, Vancouver, BC, Canada, University of California-San Diego, La Jolla, CA.

Activation of WNT signaling in CD4$^+$ T cells promotes immune suppression in pancreatic cancer. Wenting Du, Rosa E. Menjivar, Katelyn Donahue, Ashley Velez-Delgado, Marina Pasca di Magliano. University of Michigan, Ann Arbor, MI.

Overcoming stromal barriers in PDA with a novel polymeric Toll-like receptor agonist. Christopher C. DuFort, Ciana L. Lopez, Martin C. Whittle, Vladimir Vlaskin, Aditi Vadodkar, Selvi Srinivasan, Patrick S. Stayton, Sunil R. Hingorani. University of Michigan, Ann Arbor, MI, University of California, San Diego, La Jolla, CA.


Fibroblast differentiation trajectories elicit regional tissue states in pancreatic cancer Barbara T. Grünwald, Curtis McCloskey, Antoine Devisse, Foram Vyas, Geoffroy Andreieux, Kazeera Aliar, Faiyaz Notta, Grainne O’Kane, Julie Wilson, Jennifer Knox, Sandra Fischer, Thomas Kislinger, Melanie Boerries, Steven Gallinger, Rama Khokha. Princess Margaret Cancer Centre, Toronto, ON, Canada, University of Freiburg, Freiburg, Germany, Ontario Institute for Cancer Research, Toronto, ON, Canada, University Health Network, Toronto, ON, Canada, Princess Margaret Cancer Centre, Toronto, Canada.

Evaluation of antitumor activity of modified-gemcitabine solid-lipid nanoparticle in pancreatic pdx models. Edward Agyare, Taylor Smith, Andriana Inkoom, Bo Han, Jose Trevino, Nkafu Bechem Ndemazie. College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, Food and Drug Administration, Silver Spring, MD, Keck School of Medicine, University of Southern California, Los Angeles, CA, Department of Surgery, College of Medicine, Virginia Commonwealth University, Richmond, VA.

Dynamic regulation of the expression of KRAS and its effectors determines the
ability of pancreatic acinar cells to initiate tumorigenesis. Patrick Jacquemin, Mohamad Assi. University of Louvain, Brussels, Belgium.

PO-110 Targeting Cathepsin B in the pancreatic stellate cells stimulates CD8+ T cell dependent anti-tumor immune response. Bharti Garg, Tejeshwar Jain, Utpreksha Vaish, Vikas Dudeja. University of Alabama at Birmingham, birmingham, AL.

PO-111 A Human Single-cell RNA Sequencing Atlas of Pancreatic Ductal Adenocarcinoma Enables Harmonized Cell Type Calling and Comprehensive Analyses of Potential Intercellular Signaling. Benedict Kinny-Köster, Melissa R. Lyman, Dimitrios N. Sidiropoulos, Melanie Loth, Alexandra B. Puscek, Laura D. Wood, Jin He, Jun Yu, Richard A. Burkhart, Elizabeth M. Jaffee, Jacquelyn W. Zimmerman, Elana J. Fertig. 1Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, 2Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 3Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD.

PO-112 Stromal reprogramming by FAK inhibition overcomes radiation resistance to allow for immune priming and response to checkpoint blockade. Varintra E. Lander, Jad I. Belle, Brett L. Knolhoff, John M. Herndon, Cedric Mpoy, Buck E. Rogers, Julie K. Schwarz, David G. DeNardo. Washington University in St. Louis, St. Louis, MO.

PO-113 The prolyl isomerase PIN1 plays a critical role in fibroblast differentiation states to support pancreatic cancer. Ellen M. Langer, Isabel A English, Vidhi Shah, Kevin MacPherson, Kayleigh M. Kresse, Brittany L. Allen-Petersen, Colin J. Daniel, Mara H. Sherman, Andrew Adel, Rosalie C. Sears. 1Oregon Health & Science University, Portland, OR, 2Purdue University, West Lafayette, IN.

PO-114 STAT3 in cancer-associated fibroblasts promotes an immunosuppressive tumor microenvironment. Julia E. Lefler, Michael Ostrowski, Catherine MarElia-Bennett. Medical University of South Carolina (MUSC), Charleston, SC.

PO-115 Effects of mesothelin exert on tumor microenvironment in pancreatic ductal adenocarcinoma. Dongliang Liu, Ethan Poteet, Zhengdong Liang, Emily Laplante, Lisa Brubaker, Sadhna Dhingra, Aleksandar Milosavljevic, Changyi Chen, Qizhi Cathy Yao. Baylor College of Medicine, Houston, TX.

PO-116 Deletion of Arginase 1 in myeloid cells alters the pancreatic cancer microenvironment. Rosa E. Menjivar, Zeribe Nwosu, Wenting Du, Katelyn Donahue, Carlos Espinoza, Ashley Velez-Delgado, Kristee Brown, Wei Yan, Christopher Halbrook, Yaqing Zhang, Costas Lyssiotis, Marina Pasca di Magliano. 1University of Michigan, Ann Arbor, MI, 2University of California Irvine, Irvine, CA.

PO-117 The role of Hippo signaling in stromal-epithelial interactions in acinar-to-ductal metaplasia and pancreatic cancer initiation. Julia Messina-Pacheco, Yasser Riazalhosseini, Zu-hua Gao, Alex Gregorieff. 1Department of Pathology, McGill University.
and the Research Institute of McGill University Health Centre, Montreal, QC, Canada.

2Department of Human Genetics, McGill University and the McGill University and Genome Quebec Innovation Centre, Montreal, QC, Canada.

PO-118 The tumor immune microenvironment is decisive in the survival of pancreatic ductal adenocarcinoma. Hosein M. Aziz, Lawlaw Saída, Willem de Koning, Andrew Stubbs, Yunlei Li, Casper H. J. van Eijck, Dana A. M. Mustafa. Erasmus University Medical Center, Rotterdam, Netherlands.

PO-119 DFMO mediated improvement in survival of an orthotopic model of pancreatic cancer is associated with modulating immune suppression in the tumor microenvironment. Sai Preethi Nakkina¹, Sarah B. Gitto², Veethika Pandey², Jordan M. Beardsley¹, Michael W. Rohr¹, Jignesh G. Parikh³, Otto Phanstiel⁴, Deborah A. Altomare¹. ¹University of Central Florida, Orlando, FL, ²University of Pennsylvania, Philadelphia, PA, ³Orlando VA Medical Center, Orlando, FL, ⁴College of Medicine, University of Central Florida, Orlando, FL.

PO-120 Differential expression of polyamine pathways in human pancreatic tumor progression and effects of polyamine blockade therapy on the in vivo pancreatic tumor microenvironment. Sai Preethi Nakkina¹, Sarah B. Gitto², Veethika Pandey², Jignesh G. Parikh³, Dirk Geerts⁴, Kenneth P. Olive⁵, Otto Phanstiel⁶, Deborah A. Altomare¹, Carlo Maurer⁷. ¹University of Central Florida, Orlando, FL, ²University of Pennsylvania, Philadelphia, PA, ³Orlando VA Medical Center, Orlando, FL, ⁴University of Amsterdam, Amsterdam, Netherlands, ⁵Columbia University Medical Center, New York, NY, ⁶College of Medicine, Orlando, FL, ⁷Klinikum rechts der Isar der TU München, Munich, Germany.

PO-121 Investigating the role of human cancer-associated fibroblasts in pancreatic cancer invasion using patient-derived PDAC organoids. Bernat Navarro-Serer, Kenna Sherman, Laura D. Wood. Johns Hopkins University School of Medicine, Baltimore, MD.

PO-122 Combined CDK and BET inhibition reprograms the tumor and stromal compartments to enhance anti-tumor immunity in immunologically-cold CDKN2A-deficient pancreatic cancer. Brian M. Olson, Alison J. Thomas, Michael B. Ware, Gregory B. Lesinski. Emory University, Atlanta, GA.

PO-123 Development of a 3D Biomimetic Metastatic Liver Niche Model for Pancreatic Cancer. Mahsa Pahlavan¹, Weikun Xiao², Flora Eun², Chang-II Hwang³, Reginald Hill². ¹Department of Biomedical Engineering, University of Southern California, Los Angeles, CA, ²Lawrence J. Ellison Institute for Transformative Medicine of USC, University of Southern California, Los Angeles, CA, ³Department of Microbiology and Molecular Genetics, College of Biological Sciences, University of California Davis, Davis, CA.

PO-124 EZH2 blockade overcomes suppression of the proinflammatory senescence-associated secretory phenotype in the pancreas and drives NK cell-mediated pancreatic tumor responses. Loretah Chibaya¹, Yvette Lopez-Diaz¹, Haibo Liu¹, Katherine C Murphy¹, John P. Morris IV², Yu-jui Ho², Janelle Simon², Wei Luan², Amanda Kulick², Lakhena Leang¹, Elisa de Stanchina², Lihua J. Zhu¹, Scott W. Lowe², Marcus Ruscetti¹. ¹University of
Massachusetts Medical School, Worcester, MA, Memorial Sloan Kettering Cancer Center, New York, NY.

PO-125 The role of KDM6A in pancreatic cancer immune microenvironment. Lin Jin, Jing Yang, Zhujun Yi, Hong S Kim, Feng Tian, Jiaqi Shi. University of Michigan, Ann Arbor, MI.

PO-126 Loss of HIF1A decreases resistance to radiation and invasiveness in pancreatic ductal adenocarcinoma. Kevin J. Tu1, Sanjit K. Roy1, Binny Bhandary2, Amit Sawant1, Hem D. Shukla1. 1University of Maryland School of Medicine, Baltimore, MD, 2University of Maryland, Baltimore, Baltimore, MD.

PO-127 A uPA/uPAR axis in both the tumor cell and stromal compartment drives PDAC disease progression. Yi Yang, Sara R. Abrahams, Aditi Kothari, Harshi Matada, Keely Davey, Alisa S. Wolberg, Matthew J. Flick. University of North Carolina, Chapel Hill, Chapel Hill, NC.

PO-128 Epigenetic and transcriptional control of the epidermal growth factor receptor (EGFR) regulates the tumor immune microenvironment in pancreatic cancer. Salina Yuan1, Jinyang Li2, Ben Stanger1, Robert Norgard3, Fangxue Yan1, Il-Kyu Kim1, Allyson Merrell4, Yoge Vela1, Yanqing Jiang1, Natarajan V. Bhanu1, Ben A. Garcia1, Robert H. Vonderheide5, Andres Blanco6, Yu H. Sun7. 1Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2Rockefeller University, New York City, NY, 3Boehringer Ingelheim, Ridgefield, CT, 4Ambys Medicines, San Francisco, CA, 5Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, 6School of Veterinary Medicine at the University of Pennsylvania, Philadelphia, PA, 7University of Rochester Medical Center, Rochester, NY.


PO-130 Macropinocytosis at the nexus of crosstalk in the pancreatic tumor microenvironment. Yijuan Zhang1, M. Victoria Recouvreux1, Michael Jung1, Koen Galencamp1, Yunbo Li2, Olga Zagnitko1, David Scott1, Andrew Lowy2, Cosimo Comissio1. 1Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 2University of California San Diego, La Jolla, CA.

PO-131 The role of liver endothelium on pancreatic cancer growth. Wei Zhang1, Michèle Wright1, Moeez Rathore1, Ali Vaziri-Gohar1, Jordan Winter2, Rui Wang2. 1Case Western Reserve University, Cleveland, OH, 2Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH.